Clay Siegall is an interesting man. He originally set out to study zoology, even earning himself a B.S. in zoology from the University of Maryland, but he ended up in medicine. It’s the perfect example of how life can throw a curveball that changes everything.
Unfortunately, Dr. Clay Siegall witnessed something that too many people witness. When he was in high school, his father developed cancer. As if that wasn’t disheartening enough, his father’s life ended too soon. Having watched a love suffer from lack of effective treatments, the young Clay Siegall decided to change the world of medicine for the better.
He later earned a Ph.D. in genetics from George Washington University. In 1998, he founded Seattle Genetics. His company focused on developing targeted therapy treatments and medicines. A few years after its founding, Seattle Genetics developed the first FDA-approved antibody drug conjugate.
That single drug has countless approved indications. They also developed more than 20 additional drugs using that one drug as a basis. That success led to many strategic partnerships with big-name drug manufacturers, including Bayer and Pfizer. Seattle Genetics is known for creating specialized drugs for disease types that have had no substantial improvements in decades.
In just a few years, Dr. Siegall grew his company into a veritable power player in cancer research. With more skilled professionals joining his company, Dr. Siegall plans for his company to excel beyond belief. Every year, they expand their list of base drugs, pipeline drugs, and the number of potential indications for each of those drugs. Seattle Genetics is quickly making its way to the number spot of 21st-century drug development. Many estimate that Dr. Siegall will be an industry authority well before 2020.
Despite his leading developments, Dr. Siegall never forgets why he got into targeted therapies. Every day is dedicated to developing better cancer treatment drugs. Dr. Siegall will not rest until old-guard cancer treatments are a thing of history. Research is showing how advanced targeted therapies are. The potential of developing more tolerable and effective drugs is inevitable.